Scinovex
Subscribe
reviewTop 10% cited

Polyethylenglykol-umhülltes (pegyliertes) liposomales Doxorubicin

Drugs · 1997 · Vol. 54(Supplement 4) · pp. 15–21
Alberto Gabizón✉Francisco J. Plaza Martín
View via DOI Publisher page
Chemotherapy-induced cardiotoxicity and mitigationCancer Treatment and PharmacologyNanoparticle-Based Drug DeliveryMedicineDoxorubicinPharmacotherapyPharmacologyGynecologyInternal medicineChemotherapy

MeSH terms

AnimalsAntibiotics, AntineoplasticDoxorubicinDrug CarriersHeart DiseasesHumansLiposomesNeoplasmsPolyethylene GlycolsDrug Delivery Systems
Citations
477
FWCI
5.42
field-weighted impact
References
28
Percentile
96%
vs. same field & year
Citations per year
Cited by
Nanotechnology for the biologist
Journal of Leukocyte Biology · 2005 · 597 citations
Challenges and strategies in anti-cancer nanomedicine development: An industry perspective
Advanced Drug Delivery Reviews · 2016 · 1,125 citations
Effect of pegylation on pharmaceuticals
Nature Reviews Drug Discovery · 2003 · 3,358 citations
Long-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancer
Gynecologic Oncology · 2004 · 431 citations
Anthrazykline in der Krebstherapie
Drugs · 1997 · 670 citations
Reduced cardiotoxicity and comparable efficacy in a phase IIItrial of pegylated liposomal doxorubicin HCl(CAELYX™/Doxil®) versus conventional doxorubicin forfirst-line treatment of metastatic breast cancer
Annals of Oncology · 2004 · 1,701 citations
References
Sterically stabilized liposomes: a hypothesis on the molecular origin of the extended circulation times
Biochimica et Biophysica Acta (BBA) - Biomembranes · 1991 · 542 citations
Citation Network

How this paper connects to the literature. Drag to explore, click any node to open that paper.